Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: Recommendations for prevention and treatment

Breast

Volumn 18, Issue 4, 2009, Pages 213-217

  Fehm, T ^a   Felsenberg, D ^b   Krimmel, M ^a   Solomayer, E ^a   Wallwiener, D ^a   Hadjii, P ^a,c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Bisphosphonates; Bone metastases; Breast cancer; Osteonecrosis of the jaw

Indexed keywords

ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; PENICILLIN V; PLACEBO; ZOLEDRONIC ACID;

ADJUVANT THERAPY; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COMORBIDITY; DEBRIDEMENT; DENTAL CARE; DENTAL SURGERY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INCIDENCE; INFECTION; JAW OSTEONECROSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; WOUND HEALING;

BONE NEOPLASMS; BREAST NEOPLASMS; COMORBIDITY; DENTAL CARE; DIPHOSPHONATES; FEMALE; HUMANS; JAW DISEASES; OSTEONECROSIS; OSTEOPOROSIS; RISK FACTORS;

EID: 69949108393     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2009.07.001     Document Type: Review

References (36)

1. Lipton A., Theriault R.L., Hortobagyi G.N., Simeone J., Knight R.D., Mellars K., et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88 (2000) 1082-1090
2. Coleman R.E. Bisphosphonates in breast cancer. Ann Oncol 16 (2005) 687-695
3. Gnant M., Mlineritsch B., Luschin-Ebengreuth G., Kainberger F., Kässmann H., Piswanger-Sölkner J.C., et al. Austrian Breast and Colorectal Cancer Study Group (ABCSG). Austrian Breast and Colorectal Cancer Study Group (ABCSG). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9 (2008) 840-849
4. Aapro M., Abrahamsson P.A., Body J.J., Coleman R.E., Colomer R., Costa L., et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19 3 (2008) 420-432
5. Hadji P., Body J.J., Aapro M.S., Brufsky A., Coleman R.E., Guise T., et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 19 8 (2008) 1407-1416
6. Rogers M.J., Watts D.J., and Russell R.G. Overview of bisphosphonates. Cancer 80 (1997) 1652-1660
7. Hillner B.E., Ingle J.N., Chlebowski R.T., Gralow J., Yee G.C., Janjan N.A., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. American Society of Clinical Oncology. J Clin Oncol 21 21 (2003) 4042-4057
8. Costa L. Bisphosphonates: reducing the risk of skeletal complications from bone metastasis. The Breast 16 (2007) 16-20
9. Khosla S., Burr D., Cauley J., Dempster D.W., Ebeling P.R., Felsenberg D., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22 (2007) 1479-1491
10. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115-1117
11. Durie B.G., Katz M., and Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353 (2005) 99-102
12. Ruggiero S.L., Mehrotra B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527-534
13. Hoff A.O., Toth B.B., Altundag K., Johnson M.M., Warneke C.L., Hu M., et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23 (2008) 826-836
14. Diel I.J., Solomayer E.F., Costa S.D., Gollan C., Goerner R., Wallwiener D., et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339 (1998 Aug 6) 357-363
15. Diel I.J., Jaschke A., Solomayer E.F., Gollan C., Bastert G., Sohn C., et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow-a long-term follow-up. Ann Oncol 19 (2008) 2007-2011
16. Powles T., McCroskey E., and Paterson A. Oral bisphosphonates as adjuvant therapy for operable breast cancer. Clin Cancer Res 12 (2006) 6301s-4s
17. Saarto T., Vehmanen L., Virkkunen P., and Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 43 7 (2004) 650-656
18. Gnant M., Mlineritsch B., Schippinger W., Luschin-Ebengreuth G., Pöstlberger S., and Menzel C. ABCSG-12 Trial Investigators: endocrine therapy plus zoledronic acid in premenopausal breast cancer. NEJM 360 (2009) 679-691
19. Brufsky A., Harker G., and Beck J.T. The effect of zoledronic acid in the prevention of aromatase inhibitor-associated bone loss on postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 36-months follow-up. Cancer Res 69 (2009) 176S
20. Eidtmann H., Bundred N.J., and De Boer R. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. Cancer Res 69 (2009) 74S
21. Burkinshaw R., Winter M., Thorpe H., Pedlar J., and Coleman R. Osteonecrosis of the jaw and dental related adverse events during adjuvant therapy for early breast cancer: initial dental safety findings from the AZURE study. Cancer Treat Rev 34 (2008) S75-S76
22. Felsenberg D., Hoffmeister B., Amling M., Mundlos S., Seibel M.J., and Fratzl P. Onkologie:Kiefernekrosen nach hoch dosierter Bisphosphonattherapie. Deutsches Ärzteblatt 103 (2006) 2681-2682
23. Bamias A., Kastritis E., Bamia C., Moulopoulos L.A., Melakopoulos I., Bozas G., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23 (2005) 8580-8587
24. Krimmel M., Hoffmann J., and Reinert S. Bisphosphonate induced osteonecrosis of the jaw - clinical course and strategies. Int J Oral Maxillofac Surg 34 (2005) 87
25. Kyrgidis A., Vahtsevanos K., Koloutsos G., Andreadis C., Boukovinas I., Teleioudis Z., et al. Bisphosphonate-related osteonecrosis of the jaws. A case-control study of risk factors in breast cancer patients. J Clin Oncol 26 (2008) 1-5
26. Weitzman R., Sauter N., Eriksen E.F., Tarassoff P.G., Lacerna L.V., Dias R., et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients. Crit Rev Oncol/Hematol 62 (2007) 148-152
27. Ruggiero S.L., Fantasia J., and Carlson E. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Prac 2 (2006) 7-14
28. Estilo C.L., Fornier M., Farooki A., Carlson D., Bohle III G., and Huryn J.M. Osteonecrosis of the jaw related to Bevacizumab. J Clin Oncol 26 (2008) 4037-4043
29. Ripamonti C.I., Maniezzo M., Campa T., Fagnoni E., Brunelli C., Saibene G., et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20 (2008) 137-145
30. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65 (2007) 367-9
31. Khan A.A., Sándor G.K., Dore E., Morrison A.D., Alsahli M., and Amin F. Canadian Association of Oral and Maxillofacial Surgeons. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 35 7 (2008) 1391-1397
32. Tubiana-Hulin M, Spielmann M, Roux C, Campone M, Zelek L, Gligorov J, et al. Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis. Crit Rev Oncol Hematol 2009;71(1):12-21.
33. Saad F., Lipton A., Cook R., Chen Y.M., Smith M., and Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110 (2007) 1860-1867
34. Abu-Id M.H., Acil Y., Gottschalk J., and Kreusch T. Bisphosphonatassozierte Osteonekrose des Kiefers. MundKieferGesichtsChir 10 (2006) 73-81
35. Pavlakis N., Schmidt R., and Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 20 3 (2005) Art. No. CD003474, DOI: 10.1002/14651858.CD003474.pub2.
36. Fehm T., Beck V., Banys M., Lipp H.P., Hairass M., Reinert S., et al. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol 112 3 (2009) 605-609